Nuvalent, Inc. is a biotech company developing new medicines.
Nuvalent, Inc. (NUVL) is expected to report earnings on Wednesday, October 28, 2026, after the close. Consensus EPS estimate is $-1.47.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2025-10-30 | Sep 2025 qtr | $-1.39 | $-1.70 | — | $0 |
| 2025-08-07 | Jun 2025 qtr | $-1.27 | $-1.39 | -9.4% | $0 |
| 2025-05-08 | Mar 2025 qtr | $-1.14 | $-1.18 | -3.5% | $0 |
| 2025-02-27 | Dec 2024 qtr | $-1.04 | $-1.05 | -1.0% | $0 |
| 2024-11-12 | Sep 2024 qtr | $-0.93 | $-1.28 | — | $0 |
| 2024-08-08 | Jun 2024 qtr | $-0.76 | $-0.88 | — | $0 |
| 2024-05-09 | Mar 2024 qtr | $-0.67 | $-0.69 | -3.0% | $0 |
| 2024-02-27 | Dec 2023 qtr | $-0.59 | $-0.62 | -5.1% | $0 |
NUVL has beaten consensus EPS in 0 of its last 5 scored quarters.
See NUVL on the live calendar →